Richards, Dawn P. http://orcid.org/0000-0003-1151-0826
Queenan, John
Aasen-Johnston, Linnea
Douglas, Heather
Hawrysh, Terry
Lapenna, Michael
Lillie, Donna
McIntosh, Emily I.
Shea, Jenna
Smith, Maureen
Marlin, Susan
Funding for this research was provided by:
Clinical Trials Ontario (N/A)
Article History
Received: 29 December 2023
Accepted: 1 May 2024
First Online: 21 June 2024
Declarations
:
: TH, ML, EM, JS, and MS received an honorarium for their efforts related to this project. DPR is a full-time employee of Five02 Labs, Inc., which is under contract to Clinical Trials Ontario to provide services related to patient and public engagement; and is the volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization which receives the majority of its funding through independent grants from pharmaceutical companies. JQ has had previous contracts with Clinical Trials Ontario to provide epidemiological consultation. LAJ is an employee of BESPOKE Business Solutions, which provided contract work to Clinical Trials Ontario in 2021–2022. HD has been provided an honorarium as part of a patient focus group and has participated in clinical trials sponsored by four pharmaceutical companies. ML has received honorarium for being a team member of a clinical trial. MS has received travel support to attend the Canadian Organization for Rare Diseases conference. SM has no conflicts. All authors filled out and submitted an ICMJE disclosure statement.